ScinoPharm and Nanjing King-friend Partner on Drug for China

ScinoPharm of Taiwan and Nanjing King-friend Biochemical Pharmaceutical, a heparin API supplier, have teamed up to develop Regadenoson for China. Developed by Astellas of Japan, Regadenoson is a coronary artery vasodilator, which is used in radionuclide myocardial perfusion imaging among patients who cannot tolerate exercise stress. Astellas has not applied for a China drug license for Regadenoson. More details.... Stock Symbol: (TWSE: 1789) Share this with colleagues: // //